期刊文献+

绝经后妇女血清MMP-13、TIMP-1水平与骨密度的相关性研究 被引量:1

Correlation of Serum Matrix Metalloproteinase-13 and Tissue Inhibitor of Matrix Metalloproteinase-1 Levels and Bone Marrow Density(BMD) in Postmenopausal Women
下载PDF
导出
摘要 目的检测绝经后妇女血清基质金属蛋白酶-13(MMP-13)和组织金属蛋白酶抑制因子-1(TIMP-1)水平,探讨与骨密度(BMD)和骨代谢指标的相关性。方法选取武汉地区48~65岁绝经后女性120例,按照wHO标准将入选女性分为骨密度正常组、低骨量组和骨质疏松组,双能X线吸收法(DEXA)测定腰椎正位、股骨颈、华氏区和大粗隆的BMD,ELISA测定血清MMP-13、TIMP-1以及雌二醇(E2)、骨保护蛋白(OPG)、骨保护蛋白配体(OPGL)、I型原胶原N端前肽(P工NP)和I型胶原交联c末端肽(CTx)的水平,计算MMP-13/TIMP-1。结果与正常组比较,骨质疏松组和低骨量组患者血清MMP-13水平显著升高,MMP-13/TIMP-1升高(P〈0.05)。骨质疏松组患者血清MMP-13与骨密度、血清E2、OPGL水平存在明显负相关(P〈0.05),与OPG、P工NP和CTX存在明显正相关(P〈0.05)。结论绝经后骨质疏松症和低骨量患者血清MMP-13和MMP-13/TIMP-1升高,可能为绝经后骨质疏松症和绝经后妇女早期骨代谢转换过程增快的表现。 Objective To examine serum levels of matrix metalloprotefnase-13(MMP-13)and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1)and their correlations with bone mineral density(BMD)and bone metabolic biomarkers in postmenopausal women. Methods Serum MMP-13, TIMP-1, estrogen(E2 ), osteoprotegerin (OPG), OPG ligand(OPGL),procollagen I N-terminal peptide(P i NP)and collagen I C-terminal telopeptide(CTX)in 120 postmenopausal female volunteers were examined using ELISA assay. The ratios of MMP 13 to TIMP-1 (MMP-13/ TIMP-1)were calculated. BMD were measured using dual energy X-ray absorptiometry. Results Compared with control group, serum MMP-13 levels and MMP-13/TIMP-1 ratio were significantly higher in patients with osteopo rosis and osteopenia(P〈0.05), In osteoporosis group, MMP-13 levels were negatively correlated with BMD, OPGL and E2 (P〈0.05)while positively correlated with OPG,P I NP and CTX(P〈0.05). Conclusion Serum MMP-13 and MMP-13 /TIMP-1 ratio were elevated in patients with osteoporosis and osteopenia. It is possibly considered to be an early stage indicating high bone turnover in postmenopausal women.
出处 《中西医结合研究》 2013年第5期231-234,共4页 Research of Integrated Traditional Chinese and Western Medicine
基金 湖北省卫生厅青年科技人才项目(No.QJX2010-48) 武汉市青年科技晨光计划项目(No.200950431215) 武汉市卫生局临床医学项目(No.WZ10C02)
关键词 基质金属蛋白酶-13 组织金属蛋白酶抑制物-1 骨密度 骨质疏松 绝经后 matrix metalloproteinase-13 tissue inhibitor of matrix metalloproteinase-1 bone mineral density osteoporosis postmenopausal
  • 相关文献

参考文献9

  • 1MANOLAGAS SC. Birth and death of bone cells., basic regulatory mechanisms and implications for the patho- genesis and treatment of osteoporosis[J. Endocr Rev, 2000,21(8) :115-137.
  • 2GALI JC. Osteoporose[J2. Acta Ortop Bras, 2001,9 (6) : 53-62.
  • 3BIRKEDAL-HANSEN EL. Role of matrix rnetallopro teinases in human periodontal diseases[-J. J Periodontol, 1993,64(10) :474 484.
  • 4ALTMAN RD. Criteria for classification of clinical osteo arthritis[J. J Rheumatol, 1991,18 (9) : 10-12.
  • 5TEITELBAUM SL. Bone resorption by osteoclasts[-J. Science,2000,289(11) :1504 1508.
  • 6SIMONET WS, LACEY DL, DUNSTAN CR, et al. Osteo- protegegerin a novel secreted protein involved in the regula tion of bone densityl[J. Ce11,1997,89(2) 309-319.
  • 7KUSANO K, MIYAURA C, INADA M, et al. Regulation of matrix metalloproteinases ( MMP-2,-3,-9, and-13 ) by interleukin-1 and interleukin-6 in mouse calvaria:associa tion of MMP induction with bone resorption[J. Endocri nology, 1998,13(3) : 1338-1345.
  • 8DAI Y. Relationships between circulating matrix metall- proteinase-3, tissue inhibitor of matrix metalloproteinase-1 levels and postmenopausal osteoporosis[-C]//Xi'an:6th International Conference on Osteoporosis and Bone Re- search, 2012.
  • 9LEWANDOWSKI KC, KOMOROWSKI J, O' CALLAGHAN CJ, et al. Increased circulating levels of matrix metalloprotein- ase2 and-9 in women with the polycystic ovary syndrome [J. J Clin Endocrin Meta,2006,91(3) 1173-1177.

同被引文献14

  • 1ManolagasSC.Birthanddeathofbonecells:basicregula-torymechanismsandimplicationsforthepathogenesisandtreatmentofosteoporosis[J].EndoerRev,2000,21(2):115-137.
  • 2PatilA,SableR,KothariR.GeneticexpressionofMMP-Matrix-mettalo-proteinases(MMP-1andMMP-13)asafunctionofanteriormandibularrepositioningapplianceonthegrowthofmandibularcondylarcartilagewithandwith-outadministrationofInsulinlikegrowthfactor(IGF-1)andTransforminggrowthfactor-B (TGF-β)[J].AngleOrthod,2012,82(6):1053-1059.
  • 3中华医学会骨质疏松和骨矿盐疾病分会.原发性骨质疏松症诊治指南:2011年[J].中华医学会骨质疏松和骨矿盐疾病杂志,2011,4(1):2-17.
  • 4NelsonHD,HumphreyLL,NygrenP,etal.Postmenopausalhormonereplacementtherapy:scientificreview[J].JAMA,2002,288(7):872-881.
  • 5CauleyJA,RobbinsJ,ChenZ,etal.Effectsofestrogenplusprogestinonriskoffractureandbonemineraldensity:theWomen′sHealthInitiativerandomizedtrial[J].JAMA,2003,290(13):1729-1738.
  • 6CummingsSR,EttingerB,DelmasPD,etal.Theeffectsoftiboloneinolderpostmenopausalwomen[J].NEnglJMed,2008,359(7):697-708.
  • 7SantenRJ,AllredDC,ArdoinSP,etal.Postmenopausalhormonetherapy:anEndocrineSocietyscientificstatement[J].JClinEndocrinolMetab,2010,95(7Suppl1):s1-s66.
  • 8BoardoftheInternationalMenopauseSociety,PinesA,SturdeeDW,etal.IMSupdatedrecommendationsonpost-menopausalhormonetherapy[J].Climacteric,2007,10(3):181-194.
  • 9MiyakoshiN,KasukawaY,LinkhartTA,etal.EvidencethatanaboliceffectsofPTHonbonerequireIGF-Ⅰingrow-ingmice[J].Endocrinology,2001,142(10):4349-4356.
  • 10YamaguchiM,OgataN,ShinodaY,etal.Insulinreceptorsubstrate-1isrequiredforboneanabolicfunctionofpara-thyroidhormoneinmice[J].Endocrinology,2005,146(6):2620-2628.

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部